SEC Comment Letter for ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221) (ARTL) — Apr 22, 2020

ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221)
Date: April 22, 2020 · CIK: 0001621221 · Accession: 0000000000-20-003450

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 22, 2020

Author

Gregory Gorgas

Form

UPLOAD

Company

ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221)

Letter

April 22, 2020 Gregory Gorgas President, Chief Executive Officer and Chief Financial Officer Artelo Biosciences, Inc. 888 Prospect Street, Suite 210 La Jolla, CA 92037 Re:Artelo Biosciences, Inc. Form 10-K for the Fiscal Year Ended August 31, 2019 Filed November 25, 2019 File No. 1-38951 Dear Mr. Gorgas: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Randy Schreckhise, Vice President, Finance and Operations

Show Raw Text

April 22, 2020
Gregory Gorgas
President, Chief Executive Officer and Chief Financial Officer
Artelo Biosciences, Inc.
888 Prospect Street, Suite 210
La Jolla, CA 92037
Re:Artelo Biosciences, Inc.
Form 10-K for the Fiscal Year Ended August 31, 2019
Filed November 25, 2019
File No. 1-38951
Dear Mr. Gorgas:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc:       Randy Schreckhise, Vice President, Finance and Operations

SecProbe.io